 Connection
Matthew Greenhawt to Omalizumab
This is a "connection" page, showing publications Matthew Greenhawt has written about Omalizumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.333 |
|
|
|
-
Anagnostou A, Bird JA, Chinthrajah S, Dribin TE, Fleischer DM, Kim E, Nowak-Wegrzyn A, Rachid R, Shaker MS, Shreffler W, Sicherer S, Tam J, Vickery BP, Virkud YV, Wang J, Young M, Greenhawt M. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2025 Jan; 155(1):62-69.e1.
Score: 0.896
-
Shaker M, Anagnostou A, Abrams EM, Lee M, Conway AE, Hsu Blatman KS, Oppenheimer J, Greenhawt M. The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2481-2489.e1.
Score: 0.871
-
Casale TB, Fiocchi A, Greenhawt M. A practical guide for implementing omalizumab therapy for food allergy. J Allergy Clin Immunol. 2024 Jun; 153(6):1510-1517.
Score: 0.858
-
Greenhawt M, Shaker M. Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care. Ann Allergy Asthma Immunol. 2020 08; 125(2):124-125.
Score: 0.657
-
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab. J Allergy Clin Immunol Pract. 2020 02; 8(2):565-572.
Score: 0.629
-
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit? Ann Allergy Asthma Immunol. 2025 Jan; 134(1):110-121.
Score: 0.220
-
Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, Greenhawt M. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis. J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2360-2369.e1.
Score: 0.158
-
Phipatanakul W, Mauger DT, Guilbert TW, Bacharier LB, Durrani S, Jackson DJ, Martinez FD, Fitzpatrick AM, Cunningham A, Kunselman S, Wheatley LM, Bauer C, Davis CM, Geng B, Kloepfer KM, Lapin C, Liu AH, Pongracic JA, Teach SJ, Chmiel J, Gaffin JM, Greenhawt M, Gupta MR, Lai PS, Lemanske RF, Morgan WJ, Sheehan WJ, Stokes J, Thorne PS, Oettgen HC, Israel E. Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021 01; 100:106228.
Score: 0.042
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|